DexCom, Inc. (NASDAQ:DXCM) today announced that Richard B. Doubleday has
been appointed to the position of Vice President of Sales where he will
oversee DexCom’s sales and sales administration functions. Mr. Doubleday
joins DexCom from Johnson & Johnson, where he spent over 21 years at
several operating companies, including the past 13 years working in the
diabetes space for both LifeScan, Inc. and Animas Corporation. Mr.
Doubleday will report to Terry Gregg, DexCom’s President and Chief
Executive Officer.
“We are delighted that Rick has agreed to lead our sales activities.
Rick brings to DexCom not only a proven track record of sales
leadership, but many professional working relationships in the diabetes
community, which is consistent with my core belief that a strong
commitment to diabetes is an essential part of building our business,”
said Mr. Gregg. “He has demonstrated success in delivering exceptional
results in organizational development, sales volume, alliance
development, market share and profit growth and Rick has dedicated much
of his career to improving the lives of people suffering with diabetes.
We are coming into a critical time for DexCom as we lead healthcare
providers and patients to an understanding of the full potential of
continuous glucose monitoring in diabetes as well as in other key
settings.”
Mr. Doubleday most recently worked as Director, Global Strategic
Alliances for the Johnson & Johnson Family of Diabetes Companies. Mr.
Doubleday joined Johnson & Johnson in May 1988 as a Retail Sales
Representative with Advanced Care Products. He moved to LifeScan in 1996
as a National Account Manager. While at LifeScan, he also served as Area
Manager, Consumer Sales, Field Sales Director, Consumer Sales, Field
Sales Director, Professional Sales and Marketing Director, Health Care
Professional Channel. In 2006, Mr. Doubleday moved to Animas Corporation
as Director, Brand Marketing, responsible for promotion, positioning and
messaging for new and existing products in the Animas portfolio. He then
served as Director of Strategic Marketing and Alliances, responsible for
developing and managing strategic alliances for Animas as well as
helping to craft the long term portfolio strategy.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is developing and
marketing continuous glucose monitoring systems for ambulatory use by
patients and by healthcare providers in the hospital.
Cautionary Statement Regarding Forward Looking Statements
DexCom is a medical device company with a limited operating history.
Successful commercialization of the company’s products is subject to
numerous risks and uncertainties, including a lack of acceptance in the
marketplace by physicians and patients, the inability to manufacture
products in commercial quantities at an acceptable cost, possible delays
in the company’s development programs, the inability of patients to
receive reimbursement from third-party payors and inadequate financial
and other resources. Certain of these risks and uncertainties, in
addition to other risks, are more fully described in the company’s
annual report on Form 10-Q for the period ending March 31, 2009, as
filed with the Securities and Exchange Commission on May 6, 2009.
DexCom, Inc.
Steven R. Pacelli, Chief Administrative Officer,
858-200-0200
www.dexcom.com
